Stock Chart
AUPH
This target is derived from long-term trendline analysis and projected growth.
Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.
Target may adjust dynamically as the stock trend reverses or accelerates.
Type: SELL growth_1yr
Strike: $15
Premium: $2.76
Expiry: Jan 15, 2027
Target: $15
Score: -91
LEAPs are long-term options (1+ year) with less time decay.
This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.
How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future
Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling
⚠️ Not a prediction. Shows trend projection only.
R-squared: 0.56
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About AUPH - Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Key Statistics
More AUPH Analysis
This AUPH stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track AUPH's price movements with trendlines, gamma walls, and key support/resistance levels.